ABIVAX

Profilo dell'azienda

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Descrizione disponibile in inglese.

Dati societari

Settore

Salute

Industria

Biotechnology

Paese

Francia

Sede

7-11 Boulevard Haussmann, 75009, Paris

Dipendenti

98

Quotazione

ABVX · Euronext Paris

Valuta

EUR

ISIN

FR0012333284

Sito web

abivax.com